Tech Company Financing Transactions
Alethio Therapeutics Funding Round
RA Capital, Sofinnova Partners and Cancer Research Institute joined a $90 million Series A funding round for Alethio Therapeutics. The financing round was recorded on 11/5/2026.
Transaction Overview
Company Name
Announced On
11/5/2026
Transaction Type
Venture Equity
Amount
$90,000,000
Round
Series A
Investors
RA Capital (Lead Investor)
Sofinnova Partners (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance its lead programme, ATX-011, through completion of Phase 1/2a studies in essential thrombocythaemia (ET) up to Phase 3 readiness, while also progressing additional MPN programmes toward IND submission.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Sovereign House, Abingdon Science Park, Barton Ln
Abingdon, OX14 3NB
UK
Abingdon, OX14 3NB
UK
Phone
Website
Email Address
Not Recorded
Overview
Alethio Therapeutics is a biotechnology company focused on developing next-generation, disease-modifying therapies for myeloproliferative neoplasms (MPNs).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Mike Grey
Chief Executive Officer
Rohit Batta
Chief Scientific Officer
Ed Ainscow
Founder
Adam Mead
Founder
Beth Psaila
VP - Bus. Development
Steve Coats
Browse more venture capital transactions:
Prev: 11/5/2026: FluoRok venture capital transaction
Next: 11/5/2026: Numica venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here come from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs